A clinical stage pharma company with development and commercialization rights to a novel treatment for GI indications wanted to gain marketing authorization in Europe. However, the European market opportunity from the payer’s perspective was still unclear. Alacrita was asked to help the company better understand the payer perspective through primary research.
First, Alacrita reviewed documentation describing the product, the target product profile (TPP), market survey information, health economic data and points of product differentiation. We recruited payers currently or recently involved in Health Technology Assessment (HTA), reimbursement and pricing decisions, at national or regional level. We prepared a payer pre-read document that incorporated the TPP as well as evidence for differentiation, health economic arguments/data, evidence generation plan and a discussion guide. Alacrita obtained views on the product’s value given the disease burden, and prospective pricing for the product. We tested the evidence required to support proposed pricing and preferred formulary position, and the possibility of pursuing multiple indications; within those, the specific sub-patient populations payers feel have the biggest unmet need.
The payer environment for innovative therapies is also becoming increasingly competitive. Leverage our team’s industry experience in pharmaceutical market access, market research and strategic planning. We will work with you to map a clear path towards optimized access and value-based pricing for your new products. Alacrita’s expert network also offers you access to senior Medical Affairs experience, which we have used to help clients drive alignment at the commercial and medical interface.